-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Editor of WuXi AppTec's content team On June 15, 2021, Umoja Biopharma announced the completion of a Series B financing of US$210 million
.
This round of financing will be used to accelerate the advancement of its in vivo genetic engineering CAR-T cell immunotherapy, establish internal manufacturing capabilities, and promote the development of pipeline projects
.
Autologous CAR-T cell therapy has achieved significant effects in the treatment of various blood cancers.
However, it usually requires collection of T cells from the patient's body for genetic engineering and expansion in vitro, and the entire process is time-consuming and labor-intensive
.
Umoja's new-generation integrated immunotherapy technology platform for the treatment of solid tumors and hematological malignancies can directly modify the patient’s immune cells so that the patient’s immune cells can directly recognize and attack tumor cells, thereby saving time and time for in vitro culture.
Cost
.
The platform is based on groundbreaking work carried out by Seattle Children's Research Institute and Purdue University, and is complemented by three core components: VivoVec in vivo delivery platform, RACR/CAR in vivo cell expansion/control Platform and TumorTag targeting molecular platform
.
Among them, the VivoVec in vivo delivery platform can transfect T cells in patients with lentivirus to generate CAR-T cells expressing chimeric antigen receptors (CAR), namely VivoCAR-T cells
.
The RACR/CAR control platform can simultaneously express rapamycin-activated cytokine receptor (RACR) on the surface of CAR-T cells, allowing the proliferation of successfully transfected CAR-T cells to be controlled by foreign drugs
.
TumorTag targeting molecules can bind to cancer cells and mark them as targets for VivoCAR-T cells to attack.
Therefore, the use of specific targeting molecules allows CAR-T therapies to target different cancer types
.
▲The principle of the new immunotherapy platform (picture source: Umoja Biopharma official website) Dr.
Andrew Scharenberg, co-founder and CEO of Umoja Biopharma, said: "Umoja has made tremendous progress in the past year, including advancing our preclinical projects.
, Expanding manufacturing capacity, and introducing key employees, to prepare for our next stage of development and growth
.
We are very happy to continue to maintain this momentum and continue to work hard to further validate this in vivo-based therapy and maximize the effectiveness of Solid tumors and hematological malignancies have an impact
.
"Reference: [1] Umoja Biopharma Closes an Oversubscribed $210 Million Series B Financing to Expand Integrated Immunotherapy Platforms and Advance Programs to the Clinic.
Retrieved June 15, 2021, from https:// Clinic/Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation
.
If you need guidance on treatment plans, please go to a regular hospital for treatment
.
.
This round of financing will be used to accelerate the advancement of its in vivo genetic engineering CAR-T cell immunotherapy, establish internal manufacturing capabilities, and promote the development of pipeline projects
.
Autologous CAR-T cell therapy has achieved significant effects in the treatment of various blood cancers.
However, it usually requires collection of T cells from the patient's body for genetic engineering and expansion in vitro, and the entire process is time-consuming and labor-intensive
.
Umoja's new-generation integrated immunotherapy technology platform for the treatment of solid tumors and hematological malignancies can directly modify the patient’s immune cells so that the patient’s immune cells can directly recognize and attack tumor cells, thereby saving time and time for in vitro culture.
Cost
.
The platform is based on groundbreaking work carried out by Seattle Children's Research Institute and Purdue University, and is complemented by three core components: VivoVec in vivo delivery platform, RACR/CAR in vivo cell expansion/control Platform and TumorTag targeting molecular platform
.
Among them, the VivoVec in vivo delivery platform can transfect T cells in patients with lentivirus to generate CAR-T cells expressing chimeric antigen receptors (CAR), namely VivoCAR-T cells
.
The RACR/CAR control platform can simultaneously express rapamycin-activated cytokine receptor (RACR) on the surface of CAR-T cells, allowing the proliferation of successfully transfected CAR-T cells to be controlled by foreign drugs
.
TumorTag targeting molecules can bind to cancer cells and mark them as targets for VivoCAR-T cells to attack.
Therefore, the use of specific targeting molecules allows CAR-T therapies to target different cancer types
.
▲The principle of the new immunotherapy platform (picture source: Umoja Biopharma official website) Dr.
Andrew Scharenberg, co-founder and CEO of Umoja Biopharma, said: "Umoja has made tremendous progress in the past year, including advancing our preclinical projects.
, Expanding manufacturing capacity, and introducing key employees, to prepare for our next stage of development and growth
.
We are very happy to continue to maintain this momentum and continue to work hard to further validate this in vivo-based therapy and maximize the effectiveness of Solid tumors and hematological malignancies have an impact
.
"Reference: [1] Umoja Biopharma Closes an Oversubscribed $210 Million Series B Financing to Expand Integrated Immunotherapy Platforms and Advance Programs to the Clinic.
Retrieved June 15, 2021, from https:// Clinic/Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation
.
If you need guidance on treatment plans, please go to a regular hospital for treatment
.
